Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

DiaSorin Inc. Liaison SARS-CoV-2 S1/S2 IgG

ASPR’s Portfolio of COVID-19 Medical Countermeasures under EUA

BARDA is supporting the development of a serology (antibody) test for COVID-19 on DiaSorin, Inc.’s LIAISON XL platform. This new COVID-19 test is a fully automated, chemiluminescent immunoassay for the qualitative detection of IgG class antibodies against the SARS-CoV-2 virus. This technology enables health care providers to test a patient for past infection. To learn more, see the award announcement.

Emergency Use Authorization

On April 24, 2020, FDA issued an Emergency Use Authorization (EUA) to allow DiaSorin, Inc.’s Liaison SARS-CoV-2 S1/S2 IgG to be used to diagnose COVID-19.

  • This page last reviewed: May 21, 2020